PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation ...

A new study suggests COPD patients experience improved lung ... in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support recommendations put forward ...

However, the market for all inhalation-related diseases, specifically idiopathic pulmonary fibrosis (IPF ... required for delivery in dry powder inhaler (DPI) devices. Drug stability and dose ...

In June 2014, the US Food and Drug Administration (FDA) approved a new formulation of inhaled insulin (Afrezza- inhalation powder). This is based on particles ... such as asthma or chronic obstructive ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Breathe helps relieve symptoms of asthma and COPD, promotes deeper breathing, targets mucus buildup, and provides a natural alternative to inhalers and steroids. Breathe is made from natural ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...